140 related articles for article (PubMed ID: 31116609)
1. Comparison of the expected rewards between probabilistic and deterministic analyses in a Markov model.
Xie X; Yeung MW; Wang Z; Wang M; Gajic-Veljanoski O; Ng V; Volodin A
Expert Rev Pharmacoecon Outcomes Res; 2020 Apr; 20(2):169-175. PubMed ID: 31116609
[No Abstract] [Full Text] [Related]
2. Understanding bias in probabilistic analysis in model-based health economic evaluation.
Xie X; Schaink AK; Liu S; Wang M; Volodin A
Eur J Health Econ; 2023 Mar; 24(2):307-319. PubMed ID: 35610397
[TBL] [Abstract][Full Text] [Related]
3. [Probabilistic Markov models in economic evaluation of health technologies: a practical guide].
Mar J; Antoñanzas F; Pradas R; Arrospide A
Gac Sanit; 2010; 24(3):209-14. PubMed ID: 20409616
[TBL] [Abstract][Full Text] [Related]
4. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
5. Core discrete event simulation model for the evaluation of health care technologies in major depressive disorder.
Vataire AL; Aballéa S; Antonanzas F; Roijen LH; Lam RW; McCrone P; Persson U; Toumi M
Value Health; 2014 Mar; 17(2):183-95. PubMed ID: 24636376
[TBL] [Abstract][Full Text] [Related]
6. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries.
Oostenbrink JB; Rutten-van Mölken MP; Monz BU; FitzGerald JM
Value Health; 2005; 8(1):32-46. PubMed ID: 15841892
[TBL] [Abstract][Full Text] [Related]
7. [Use of probabilistic methods in economic evaluation of health technologies].
Darbà J
Gac Sanit; 2006; 20(1):74-7. PubMed ID: 16539999
[TBL] [Abstract][Full Text] [Related]
8. Early assessment of the likely cost-effectiveness of a new technology: A Markov model with probabilistic sensitivity analysis of computer-assisted total knee replacement.
Dong H; Buxton M
Int J Technol Assess Health Care; 2006; 22(2):191-202. PubMed ID: 16571195
[TBL] [Abstract][Full Text] [Related]
9. The use of probabilistic decision models in technology assessment : the case of total hip replacement.
Briggs A; Sculpher M; Dawson J; Fitzpatrick R; Murray D; Malchau H
Appl Health Econ Health Policy; 2004; 3(2):79-89. PubMed ID: 15702945
[TBL] [Abstract][Full Text] [Related]
10. [Discrete-event simulation models in the economic evaluation of health technologies and health products].
Rodríguez Barrios JM; Serrano D; Monleón T; Caro J
Gac Sanit; 2008; 22(2):151-61. PubMed ID: 18420015
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness of Total Knee Arthroplasty vs Nonoperative Management in Normal, Overweight, Obese, Severely Obese, Morbidly Obese, and Super-Obese Patients: A Markov Model.
Ponnusamy KE; Vasarhelyi EM; Somerville L; McCalden RW; Marsh JD
J Arthroplasty; 2018 Jul; 33(7S):S32-S38. PubMed ID: 29550168
[TBL] [Abstract][Full Text] [Related]
12. The cost effectiveness and cost utility of valsartan in chronic heart failure therapy in Italy: a probabilistic markov model.
Pradelli L; Iannazzo S; Zaniolo O
Am J Cardiovasc Drugs; 2009; 9(6):383-92. PubMed ID: 19929036
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in the United Kingdom.
Nazir J; Maman K; Neine ME; Briquet B; Odeyemi IA; Hakimi Z; Garnham A; Aballéa S
Value Health; 2015 Sep; 18(6):783-90. PubMed ID: 26409605
[TBL] [Abstract][Full Text] [Related]
14. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.
Garside R; Pitt M; Somerville M; Stein K; Price A; Gilbert N
Health Technol Assess; 2006 Mar; 10(8):1-142, iii-iv. PubMed ID: 16545207
[TBL] [Abstract][Full Text] [Related]
15. Probabilistic Markov Model Estimating Cost Effectiveness of Methylphenidate Osmotic-Release Oral System Versus Immediate-Release Methylphenidate in Children and Adolescents: Which Information is Needed?
Schawo S; van der Kolk A; Bouwmans C; Annemans L; Postma M; Buitelaar J; van Agthoven M; Hakkaart-van Roijen L
Pharmacoeconomics; 2015 May; 33(5):489-509. PubMed ID: 25715975
[TBL] [Abstract][Full Text] [Related]
16. Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model.
Bardach AE; Garay OU; Calderón M; Pichón-Riviére A; Augustovski F; Martí SG; Cortiñas P; Gonzalez M; Naranjo LT; Gomez JA; Caporale JE
BMC Public Health; 2017 Feb; 17(1):152. PubMed ID: 28148228
[TBL] [Abstract][Full Text] [Related]
17. Estimating the Societal Benefits of THA After Accounting for Work Status and Productivity: A Markov Model Approach.
Koenig L; Zhang Q; Austin MS; Demiralp B; Fehring TK; Feng C; Mather RC; Nguyen JT; Saavoss A; Springer BD; Yates AJ
Clin Orthop Relat Res; 2016 Dec; 474(12):2645-2654. PubMed ID: 27699631
[TBL] [Abstract][Full Text] [Related]
18. When does economic model type become a decisive factor in health technology appraisals? Learning from the expanding treatment options for relapsing-remitting multiple sclerosis.
Noon KM; Montgomery SM; Adlard NE; Kroes MA
J Med Econ; 2018 Oct; 21(10):983-992. PubMed ID: 29923439
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer.
Sherman SK; Lange JJ; Dahdaleh FS; Rajeev R; Gamblin TC; Polite BN; Turaga KK
JAMA Oncol; 2019 Feb; 5(2):236-242. PubMed ID: 30489611
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of the SAPIEN 3 TAVI valve compared with surgery in intermediate-risk patients.
Goodall G; Lamotte M; Ramos M; Maunoury F; Pejchalova B; de Pouvourville G
J Med Econ; 2019 Apr; 22(4):289-296. PubMed ID: 30547704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
